Impact of omalizumab therapy on the course of COVID-19 in a patient with severe asthma: A case report
Open Access
- 6 February 2023
- journal article
- research article
- Published by Uniwersytet Warminsko-Mazurski in Polish Annals of Medicine
- p. 1-5
Abstract
Introduction: Various risk factors have been attributed to coronavirus disease 19 (COVID-19) severity. Omalizumab as an immunoglobulin E blocker that enhances anti-viral immunity might be a potential cytokine storm trigger. Aim: Our goal was to investigate if the treatment with omalizumab due to severe asthma is a risk factor of severe COVID-19 pneumonia and if severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can trigger asthma exacerbation. Case study: We report the case of a 65-year-old patient with severe allergic asthma receiving treatment with omalizumab for last 8 months with good results, who in December 2020 was infected with SARS-CoV-2. The patient was not vaccinated against COVID-19 (no vaccine was available at that time), and had comorbidities. Results and discussion: COVID-19 course of presented patient was asymptomatic and resolved quickly without the need for hospitalization or asthma exacerbation. There was a slightly worse score on the asthma control questionnaire after COVID-19 resolution (2.1 point vs. 1.5 points) and a threefold increase in eosinophil counts (660 cell/µL vs. 230 cell/µL). However, no wheezing or deterioration in pulmonary function tests were found. A computed tomography of the chest revealed only minor densities of pulmonary parenchyma and thickened walls of bronchi. Conclusions: Omalizumab used in the treatment of severe allergic asthma proved to be safe and beneficial for the course of COVID-19 in the case reported. Simultaneously, SARS-CoV-2 was not a factor for asthma exacerbation.Keywords
This publication has 32 references indexed in Scilit:
- Eosinophil responses during COVID-19 infections and coronavirus vaccinationJournal of Allergy and Clinical Immunology, 2020
- Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational StudyAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cellsRespiratory Investigation, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, ChinaAllergy, 2020
- Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2020
- Enhanced plasmacytoid dendritic cell antiviral responses after omalizumabJournal of Allergy and Clinical Immunology, 2018
- Interferon at the crossroads of allergy and viral infectionsJournal of Leukocyte Biology, 2015
- How rhinovirus infections cause exacerbations of asthmaClinical & Experimental Allergy, 2014
- Role of deficient type III interferon-λ production in asthma exacerbationsNature Medicine, 2006